CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors
SAN DIEGO–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions….
SAN DIEGO–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions….
SAN FRANCISCO–(BUSINESS WIRE)–Lang.ai has announced its completion of a $10.5M Series A led by Nava…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA assigns preliminary ratings to five classes of notes issued by Carvana Auto…
RESTON, Va.–(BUSINESS WIRE)–$IWLLC #CEOs—Intelligent Waves (IW), a leading IT integrator that provides mission-focused, multi-domain operational…
Within two months the beauty brand saw a 60% increase in conversion rate and doubled…
Smartest, most-awarded panel on the market now available for order from electrical distribution centers Innovative…
Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan) WALTHAM, Mass.,…
– AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma– AUTO1/22: oral…
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — In a release issued under the same…
Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed…
ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells…
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine…
Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical…
Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing…
Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th…
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of…
Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients…
New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1…
Houston, Texas, USA, May 12, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. of Houston, Texas, a…